Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes

Yaribeygi, Habib; Maleki, Mina; Sathyapalan, Thozhukat; Jamialahmadi, Tannaz; Sahebkar, Amirhossein

Abstract

GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones. There is emerging evidence that they have anti-inflammatory effects. Since most long-term complications of diabetes have a background of chronic inflammation, these agents may be beneficial against diabetic complications not only due to their hypoglycemic potential but also via their anti-inflammatory effects. However, the exact molecular mechanisms by which GLP-1RAs and DPP-4i exert their anti-inflammatory effects are not clearly understood. In this review, we discuss the potential molecular pathways by which these incretin-based therapies exert their anti-inflammatory effects.

Citation

Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020). Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes. Life Sciences, 241, Article 117152. https://doi.org/10.1016/j.lfs.2019.117152

• Journal Article Type: Review
• Acceptance Date: Dec 8, 2019
• Online Publication Date: Dec 13, 2019
• Publication Date: Jan 15, 2020
• Deposit Date: Dec 18, 2019
• Publicly Available Date: Dec 14, 2020
• Journal: Life Sciences
• Print ISSN: 0024-3205
• Electronic ISSN: 1879-0631
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 241
• Article Number: 117152
• DOI: https://doi.org/10.1016/j.lfs.2019.117152
• Keywords: General Pharmacology, Toxicology and Pharmaceutics; General Biochemistry, Genetics and Molecular Biology; General Medicine; GLP-1 receptor agonist; DPP-4 inhibitor; Diabetes mellitus; Diabetic complication; Inflammation
• Public URL: https://hull-repository.worktribe.com/output/3327318
• Additional Information: This article is maintained by: Elsevier; Article Title: Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes; Journal Title: Life Sciences; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.lfs.2019.117152; Content Type: article; Copyright: © 2019 Elsevier Inc. All rights reserved.